Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]

  • In development
  • GID-TA11749
  • Expected publication date: 
To appraise the clinical and cost effectiveness of Tafasitamab + Lenalidomide + R-CHOP within its marketing authorisation for treating lymphoma